Allergic bronchopulmonary aspergillosis

Tillie‐Leblond, I.; Tonnel, A. B.

doi:10.1111/j.1398-9995.2005.00887.x

Cited by 170 publications

(71 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other authors (11) have reported that rAspf3 and rAspf4 allow discrimination between ABPA and non-ABPA patients with atopic A. fumigatus-positive skin tests. According to the data in the literature (2,11,21), rAspf4 (a cytoplasmic protein with unknown function) and rAspf6 recombinants have provided powerful tools for the accurate diagnosis of ABPA. Kraemer et al (13) have shown that allergen-specific IgE against these two recombinants could be detected almost exclusively in the sera of patients with ABPA.…”

Section: Discussionmentioning

confidence: 99%

“…Minor diagnostic criteria include repeated detection of Aspergillus species in sputum samples, a history of expectoration of brown plugs or flecks, and late skin reactivity to Aspergillus antigens. Despite these criteria, diagnosis of ABPA in cystic fibrosis patients remains particularly difficult (3,16,21,22). Therefore, as stated in the most recent consensus document on the diagnosis and therapy of ABPA in cystic fibrosis patients (19), serological findings should strongly contribute to the confirmation or exclusion of clinically suspected ABPA.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Recombinant Allergens Combined with Biological Markers in the Diagnosis of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis Patients

Fricker‐Hidalgo

Coltey

Llerena

et al. 2010

Clin Vaccine Immunol

View full text Add to dashboard Cite

Allergic bronchopulmonary aspergillosis (ABPA) is a frequent complication in cystic fibrosis patients. The diagnosis remains difficult and requires a combination of clinical, radiological, biological, and mycological criteria. The aim of this study was to analyze the added value of two recombinant antigens, rAspf4 and rAspf6, associated with the detection of specific IgG; precipitins; total IgE; and Aspergillus fumigatus in sputum for the diagnosis of ABPA. In a retrospective study, we determined the specific IgE responses to these recombinants in 133 sera of 65 cystic fibrosis patients. We selected an average of five serum samples from each of the 17 patients with ABPA (13 proven and 4 probable ABPA) and from 3 patients with Aspergillus bronchitis and rhinosinusitis. One serum sample for the 45 patients without ABPA was tested. The sensitivity of specific IgE detection against rAspf4 calculated per patient (92.3%) was significantly higher (P < 0.05) than that of rAspf6 (53.8%). When rAspf4 IgE detection was associated with anti-Aspergillus IgG enzyme-linked immunosorbent assay (ELISA) and precipitin detection, the sensitivity rose to 100%. The specificities of rAspf4 and rAspf6 IgE detection were 93.7% and 91.6%, respectively. Other diagnostic criteria had slightly lower specificities (87.5% for anti-Aspergillus IgG ELISA, 89.6% for precipitins, 84.4% for total IgE, and 85.0% for positive A. fumigatus culture in sputum). In conclusion, this retrospective study showed the relevance of rAspf4 IgE detection, in combination with other biological markers (Aspergillus IgG ELISA, precipitins, and total IgE), for improving the biological diagnosis of ABPA.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Recombinant Allergens Combined with Biological Markers in the Diagnosis of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis Patients

Fricker‐Hidalgo

Coltey

Llerena

et al. 2010

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…Aberrant immune responses to A. fumigatus result in a spectrum of human diseases that include allergic bronchopulmonary aspergillosis. In severe cases, this leads to pulmonary hypersensitivity and compromised lung function, which is called farmer's lung (26). A mild form of infection is the colonization of cavities within the lung, known as aspergilloma or a fungal ball, and is often found in immunocompetent people who have recovered from a Mycobacterium tuberculosis infection (14).…”

mentioning

confidence: 99%

Aspergillus fumigatusDoes Not Require Fatty Acid Metabolism via Isocitrate Lyase for Development of Invasive Aspergillosis

et al. 2007

View full text Add to dashboard Cite

Aspergillus fumigatus is the most prevalent airborne filamentous fungus causing invasive aspergillosis in immunocompromised individuals. Only a limited number of determinants directly associated with virulence are known, and the metabolic requirements of the fungus to grow inside a host have not yet been investigated. Previous studies on pathogenic microorganisms, i.e., the bacterium Mycobacterium tuberculosis and the yeast Candida albicans, have revealed an essential role for isocitrate lyase in pathogenicity. In this study, we generated an isocitrate lyase deletion strain to test whether this strain shows attenuation in virulence. Results have revealed that isocitrate lyase from A. fumigatus is not required for the development of invasive aspergillosis. In a murine model of invasive aspergillosis, the wild-type strain, an isocitrate lyase deletion strain, and a complemented mutant strain were similarly effective in killing mice. Moreover, thin sections demonstrated invasive growth of all strains. Additionally, thin sections of lung tissue from patients with invasive aspergillosis stained with anti-isocitrate lyase antibodies remained negative. From these results, we cannot exclude the use of lipids or fatty acids as a carbon source for A. fumigatus during invasive growth. Nevertheless, test results do imply that the glyoxylate cycle from A. fumigatus is not required for the anaplerotic synthesis of oxaloacetate under infectious conditions. Therefore, an antifungal drug inhibiting fungal isocitrate lyases, postulated to act against Candida infections, is assumed to be ineffective against A. fumigatus.

show abstract

“…It can cause allergic bronchopulmonary aspergillosis, pulmonary aspergilloma and invasive aspergillosis. In the latter the symptoms can be cough, fever, lowgrade chest pain, dyspnea and hemoptysis (2) while in allergic bronchopulmonary aspergillosis malaise, fever, presence of sputum plugs and purulent sputum, cough, chest pain, and hemoptysis can be observed beside the symptoms of asthma (23). The pulmonary aspergilloma can cause hemoptysis or it can be without symptoms.…”

Section: Introductionmentioning

confidence: 99%

In vivo application of a small molecular weight antifungal protein of Penicillium chrysogenum (PAF)

Palicz

Jenes

Gáll

et al. 2013

Toxicology and Applied Pharmacology

View full text Add to dashboard Cite

The small antifungal protein secreted by Penicillium chrysogenum (PAF) inhibits the growth of important zoo pathogenic filamentous fungi, including members of the Aspergillus family.It was shown previously that PAF has no toxic effects on mammalian cells in vitro. We carried out safety experiments by investigating the in vivo effects of PAF by inoculating adult C57/B16 mice with PAF intranasally. Animals were randomly divided into six groups and subjected to different PAF concentrations, up to 54 µg, either once a week for up to 8 weeks or once every day for two weeks. Animals neither died due to the treatment nor were any side effects observed. Histological examinations did not find any pathological reaction in the liver, in the mucous membrane of the nose, and in the lungs, even in the highest concentration used.Mass spectrometry revealed that ZZZ. The effect of the drug on the skin was examined in an irritative dermatitis model by measuring the thickness of the ears. This proved to be the same following PAF application as in control (23.8±9.2 vs. 22.5±5.0 µm, respectively) and significantly less than when treated with phorbol-12-myristate-13-acetate (PMA; 57.5±29.2 µm) used as positive control. Histological changes relative to control were present only in the case of PMA. Positron emission tomography was used to follow potential inflammation of the lungs. Neither the application of control saline nor that of PAF induced any inflammation while the positive control lipopolysaccharide did. Since no toxic effects of PAF were found either in intranasal application or in local external treatment, our result is the first step for introducing PAF as potential antifungal drug in human therapy.

show abstract

Allergic bronchopulmonary aspergillosis

Cited by 170 publications

References 86 publications

Recombinant Allergens Combined with Biological Markers in the Diagnosis of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis Patients

Recombinant Allergens Combined with Biological Markers in the Diagnosis of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis Patients

Aspergillus fumigatusDoes Not Require Fatty Acid Metabolism via Isocitrate Lyase for Development of Invasive Aspergillosis

In vivo application of a small molecular weight antifungal protein of Penicillium chrysogenum (PAF)

Contact Info

Product

Resources

About